Physician profile
Jeffrey Marshall
NPI 1780978114
$4,939.04
in general payments reported to CMS, 2019-2025
21 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,719 · 2020: $210 · 2021: $42.22 · 2022: $389 · 2023: $1,838 · 2024: $633 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,349 · Food and Beverage: $1,062 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,349.01 |
| Food and Beverage | $1,061.98 |
| Education | $167.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $1,862.50 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Veran Medical Technologies, INC. | $1,495.77 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $321.88 | 2022-2025 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $254.17 | 2020-2024 | Nucala, Trelegy Ellipta |
| Cardiovascular Systems INC. | $187.50 | 2019 | |
| Vero Biotech INC. | $158.85 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $145.65 | 2022-2023 | Dupixent |
| Grifols USA, LLC | $107.89 | 2022-2023 | Prolastin-C Liquid |
| United Therapeutics Corporation | $79.28 | 2019-2024 | Orenitram, Remodulin |
| Astrazeneca Pharmaceuticals LP | $43.64 | 2023 | Fasenra |
| Intuitive Surgical, INC. | $41.24 | 2024-2025 | |
| Pulmonx Corporation | $41.12 | 2022 | |
| Harmony Biosciences LLC | $37.49 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.68 | 2024 | Ofev |
| Ambu INC. | $29.33 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $22.80 | 2023 | Xolair |
| Genzyme Corporation | $22.57 | 2020 | |
| Pfizer INC. | $21.23 | 2023 | |
| Insmed, INC. | $18.38 | 2024 | Arikayce |
| Resmed Corp | $18.07 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.